NRIX
Price:
$19.34
Market Cap:
$1.37B
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell th...[Read more]
Industry
Biotechnology
IPO Date
2020-07-24
Stock Exchange
NASDAQ
Ticker
NRIX
According to Nurix Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.30B. This represents a change of 43.04% compared to the average of 907.51M of the last 4 quarters.
The mean historical Enterprise Value of Nurix Therapeutics, Inc. over the last ten years is 594.23M. The current 1.30B Enterprise Value has changed 21.74% with respect to the historical average. Over the past ten years (40 quarters), NRIX's Enterprise Value was at its highest in in the August 2024 quarter at 1.76B. The Enterprise Value was at its lowest in in the May 2019 quarter at 0.
Average
594.23M
Median
549.19M
Minimum
280.59M
Maximum
1.17B
Discovering the peaks and valleys of Nurix Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 150.77%
Maximum Annual Enterprise Value = 1.17B
Minimum Annual Increase = -52.96%
Minimum Annual Enterprise Value = 280.59M
Year | Enterprise Value | Change |
---|---|---|
2023 | 313.97M | -42.89% |
2022 | 549.74M | -52.96% |
2021 | 1.17B | 113.03% |
2020 | 548.65M | -22.03% |
2019 | 703.63M | 150.77% |
The current Enterprise Value of Nurix Therapeutics, Inc. (NRIX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
677.50M
5-year avg
656.95M
10-year avg
594.23M
Nurix Therapeutics, Inc.’s Enterprise Value is greater than Foghorn Therapeutics Inc. (255.47M), greater than Shattuck Labs, Inc. (12.54M), greater than Monte Rosa Therapeutics, Inc. (351.25M), less than Kymera Therapeutics, Inc. (2.62B), greater than C4 Therapeutics, Inc. (277.45M), greater than Arvinas, Inc. (1.18B), less than Eliem Therapeutics, Inc. (0), greater than Prelude Therapeutics Incorporated (70.32M), greater than Relay Therapeutics, Inc. (600.62M), greater than Stoke Therapeutics, Inc. (450.28M), greater than Pliant Therapeutics, Inc. (796.64M), greater than Black Diamond Therapeutics, Inc. (121.51M), greater than Nkarta, Inc. (190.09M), greater than Lyell Immunopharma, Inc. (133.36M), greater than Generation Bio Co. (141.59M), greater than Sana Biotechnology, Inc. (355.10M),
Company | Enterprise Value | Market cap |
---|---|---|
255.47M | $274.07M | |
12.54M | $52.75M | |
351.25M | $433.13M | |
2.62B | $2.65B | |
277.45M | $270.00M | |
1.18B | $1.26B | |
0 | $342.68M | |
70.32M | $63.31M | |
600.62M | $703.16M | |
450.28M | $598.00M | |
796.64M | $816.05M | |
121.51M | $121.94M | |
190.09M | $161.60M | |
133.36M | $182.22M | |
141.59M | $69.46M | |
355.10M | $386.01M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nurix Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Nurix Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Nurix Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Nurix Therapeutics, Inc. (NRIX)?
What is the 3-year average Enterprise Value for Nurix Therapeutics, Inc. (NRIX)?
What is the 5-year average Enterprise Value for Nurix Therapeutics, Inc. (NRIX)?
How does the current Enterprise Value for Nurix Therapeutics, Inc. (NRIX) compare to its historical average?